Member Info for Chelsea11

EE - clearly the trial update is super-critical. I agree.

Don’t agree AACR is a side-issue, or in fact an “issue” at all.

Can you imagine the volume of doom on here, if Scancell had decided not to register to attend and promote Modi lol

We’re there. The poster is there. Lindy is there. Folks will be listening to her.

The poster presentation could be a catalyst and springboard for further, important discussion that takes the Company forward from where it is today. It’s an enabler and at a prestigious industry event attended in person by the great and the good. The audience may find the poster content compelling.

Personally, I see no negatives.

Yup, that’s what I posted yesterday:

“Who knows but I would also believe that she (or any other Scancell rep that might be present), would be free to discuss the content of any Modi RNS ALREADY issued ie. along the “very encouraging” line :-)” - (outside of the scheduled poster presentation).

If there is a cherry on the top of that by way of a new, updated Modi RNS, we could be in for a very interesting week.

And if you have time, I’d recommend reading the 2022 AACR Impact Report. It wasn’t until I read this that I got the full perspective of the magnitude of the AACR event. Some of the information, like the numbers around media coverage for example, are startling! The “science types” on here will know this (and in fact Berm’s previous posts prompted me to research) but suspect others may not.

https://annualreport2022.aacr.org/

Oops here’s the link………

https://www.aacr.org/meeting/aacr-ahns-head-and-neck-cancer-conference-innovating-through-basic-clinical-and-translational-research/

I also previously mentioned the AACR Head & Neck Conference in Montreal, July 7th-8th, as wondered if Scancell might be represented there, given the Modi progress we have heard about to date.

Abstract Submission Deadline for that one, is Thursday April 20th at 12pm ET.

These?

https://www.abstractsonline.com/pp8/#!/10828/sessions/@sessiontype=Late-Breaking%20Poster%20Session/1

To be explicit, I’m talking outside the presentation of course.

Who knows but I would also believe that she (or any other Scancell rep that might be present), would be free to discuss the content of any Modi RNS ALREADY issued ie. along the “very encouraging” line :-)

Hi WTP. My stab at a high level. Happy for anyone to correct me!

During the formal and pre-scheduled presentation, Lindy can only talk with the boundaries of the material provided to AACR. As has been posted previously, what Modi is but not what it has done to date.

However, there could be an RNS containing a Modi update issued prior to the close of AACR and that must surely mean Lindy could discuss that with anyone - outside of the presentation.

Like I said, if anyone believes differently, I would welcome being corrected.

“ The AACR Annual Meeting highlights the latest, most exciting discoveries in every area of cancer research and provides a unique opportunity for investigators from all over the world to meet, interact, and share their insights. This year’s meeting theme - “Bringing Cancer Discoveries to Patients” - underscores the vital and inextricable link between discovery and treatment, and it reinforces the fact that research underpins all the progress being made in the field toward cancer cures.”

Whatever the outcome from the event this time, isn’t it just great to be supporting and contributing to the above!

That will be Haribo, demonstrating his “Holding Strong” strategy :-)

Peter Crouch?

Linked to JB1’s explanation…….

If anyone wanted to look at the 2022 Press Program (or indeed prior years)

https://www.aacr.org/about-the-aacr/newsroom/annual-meeting/2022-press-program/

The specific time, from the AACR website……….

“ The text of the clinical trial and late-breaking abstracts will be posted to the planner at 12 noon ET on Friday, April 14.”

I guess whichever pole you tie your flag to, the document has sparked conversation that is truly Scancell relevant and interesting, as opposed to some totally random stuff lifted off the web and posted here with no supporting contextual note.

As discussed here yesterday, the timing of the publication could turn out to be very significant. We’ll soon find out!

They were all very busy yesterday:

https://www.daysoftheyear.com/days/hamster-day/

Best of luck today everyone. Hopefully an assault on 20p.

Sorry Ipad but you did say we’ve heard nothing since Oct 22!

Ipad - but we have heard since Oct 22, in the Interims.

· Received licence fee of £5.3 million relating to the up-front payment receivable from Genmab following the signing of the licence agreement in October 2022.